AbCellera Biologics Inc. · Q2 2025
ReportedAug 7, 2025
Period endedJun 30, 2025
Rule of 40n/m
The quarter in short
Revenue $17M, up 133.3% year over year and 303.4% on the quarter. EPS −$0.12, up 7.7% year over year and 20.0% on the quarter. Free cash flow −$46M, up 8.6% year over year and down 106.3% on the quarter.
Reported this quarter
Revenue
$17M
QoQ +303.4%
YoY +133.3%
EPS
−$0.12
QoQ +20.0%
YoY +7.7%
Free Cash Flow
−$46M
QoQ −106.3%
YoY +8.6%
FCF Margin
-267.9%
QoQ +256.1 pp
YoY +415.9 pp
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1703057.
HTML
8-K results announcement
Filed Aug 7, 2025
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
165 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
12 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-Q quarterly report
Period ended Jun 30, 2025, filed Aug 7, 2025
ZIP
XBRL data bundle
Structured financial statements from the 10-Q
JSON
Company facts (XBRL)
Every figure ABCL has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q2 2025, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings